52 Week Range
As of on the New York Stock Exchange ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
U.S. Food And Drug Administration Approves Opdivo In Combination With Cabometyx As First-Line Treatment For Patients With Advanced Renal Cell Carcinoma
U.S. Food And Drug Administration Accepts For Priority Review Application For Opdivo® (Nivolumab) Combined With Chemotherapy
U.S. Food And Drug Administration Accepts For Priority Review Application For Opdivo® (Nivolumab) As Adjuvant Therapy For Patients With Resected Esophageal Or Gastroesophageal Junction Cancer
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world. Its subsidiaries are Celgene Corp and MyoKardia, Inc.
Biotechnology & Drugs
430 E 29th St Fl 14
NEW YORK, NY
Chairman of the Board, Chief Executive Officer
David V. Elkins
Executive Vice President and Chief Financial Officer Member of the Leadership Team
Ann Powell Judge
Chief Human Resource Officer, Senior Vice President Member of the Leadership Team
Executive Vice President, General Counsel
John E. Elicker
Executive Vice President of Investor Relations
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Bristol Myers Squibb said on Monday that its current drug pipeline has the ability to replace up to $25 billion a year in lost revenue from patent expirations by the end of the decade.
Bristol Myers Squibb said on Monday the U.S. health regulator has deferred a decision on an experimental blood cancer therapy that it acquired in the $74 billion buyout of Celgene due to coronavirus-related travel restrictions.
Bristol Myers Squibb Co on Thursday posted better-than-expected third-quarter earnings, with most of its top-selling drugs outperforming Wall Street forecasts, as many Americans resumed routine medical care they had put off earlier in the coronavirus pandemic.
Bristol Myers Squibb Co said on Tuesday its experimental plaque psoriasis oral drug proved more effective in clearing moderate to severe cases of the skin condition than placebo or Amgen Inc's Otezla in a late-stage study.
The U.S. National Institutes of Health (NIH) has started a late-stage trial to evaluate if immune-modulating therapies from three drugmakers can help reduce the need for ventilators for COVID-19 patients and shorten their hospital stay.
Bristol Myers Squibb Co said on Wednesday its cancer drug Opdivo plus chemotherapy helped more patients with a form of lung cancer become free of the disease versus chemotherapy alone in a late-stage trial. Significantly more non-small cell lung cancer (NSCLC) patients receiving...
Bristol Myers Squibb Co said on Wednesday its blockbuster cancer immunotherapy, Opdivo, met the main goal of pathologic complete response, or the absence of cancer cells, in a late-stage study in patients with a type of lung cancer.
At least nine law firms scored work on healthcare deals announced this week, capitalizing on a sector that has stayed hot while other industries catch up from the pandemic's economic chill.
Bristol Myers Squibb Co said on Monday it would buy MyoKardia Inc for about $13 billion to bolster its portfolio of heart disease treatments, ahead of the potential loss of sales exclusivity of some of its blockbuster drugs.
U.S. drugmaker Bristol-Myers Squibb Co said on Monday it would buy heart drugs developer MyoKardia Inc for about $13 billion.
A Manhattan federal judge has dismissed a shareholder suit against Bristol Myers Squibb, finding that investors did not plausibly allege the pharmaceutical company's description of a 2015 drug trial was misleading or that the industry had a standard definition for a key...
A federal appeals court has revived a whistleblower lawsuit accusing Sanofi-Aventis and Bristol-Myers Squibb of falsely marketing their blood-thinner drug Plavix, finding that a lower court dismissed it based on a misreading of the False Claims Act's "first-to-file" bar.
Bristol Myers Squibb Co <BMY.N> on Thursday raised its annual profit forecast as it predicted a recovery in sales of its hospital-administered drugs, which had taken a hit to demand as patients avoided doctors' offices due to the COVID-19 pandemic.
Bristol Myers Squibb Co raised its annual profit forecast on Thursday on hopes of a recovery in demand for its hospital-administered drugs, which had dropped as patients stayed away from doctors' offices due to the COVID-19 pandemic.
* DRAGONFLY THERAPEUTICS ANNOUNCES NEW RESEARCH COLLABORATION WITH BRISTOL MYERS SQUIBB TO DEVELOP NOVEL THERAPEUTIC CANDIDATES FOR MULTIPLE SCLEROSIS AND NEURO-INFLAMMATION TARGET
* AGIOS AND ROYALTY PHARMA ANNOUNCE $255 MILLION PURCHASE AGREEMENT FOR IDHIFA® ROYALTY
* BRISTOL-MYERS SQUIBB CO - DECLARED A QUARTERLY DIVIDEND OF FORTY-FIVE CENTS PER SHARE ON $.10 PAR VALUE COMMON STOCK OF CORPORATION Source text for Eikon: Further company coverage:
* JOUNCE THERAPEUTICS REGAINS WORLDWIDE RIGHTS TO JTX-8064 FROM BRISTOL MYERS SQUIBB
* NEW DATA REINFORCE IMPROVED AND DURABLE CLINICAL RESPONSES OF ORENCIA IN MODERATE-TO-SEVERE EARLY RHEUMATOID ARTHRITIS PATIENTS WITH AUTOANTIBODIES LINKED TO MORE SEVERE DISEASE
* BRISTOL MYERS - ANNOUNCES TOPLINE RESULTS FROM PHASE 3 TRUE NORTH TRIAL EVALUATING ZEPOSIA IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.